On the stock market since 2021, it operates in the world of health and science. It has 451 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Average growth of 45% a year over the last 3 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 85% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 45% a year on average.
Sales run at $97.7M a year. A small number, but proof the product has real buyers.
There is $539.6M in the vault; even if every debt were paid off, $537.1M would remain.
A loss of $109.2M against $97.7M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, SLGC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SLGC is a high-risk stock — not yet profitable, and its future rides on its product catching on.